Topic Archives: Galmed (GLMD)

June 9, 2021 / Travis Johnson, Stock Gumshoe

What’s up with Stansberry Venture’s “Major FDA Announcement” Pitch?

This is the pitch that sent a bucketful of questions heading our way yesterday: “Last Week’s Major FDA Announcement Officially Kick-started a Massive Opportunity “A disease that 42% of Americans suffer from can now be cured. Our analyst tracked this story from the beginning, and he’s finally breaking his silence to reveal the name of […]

March 24, 2015 / DrKSSMDPhD

The Great Gallic Foie Gras Hack

“I firmly believe that if the whole materia medica could be sunk to the bottom of the sea, it would be all the better for mankind and all the worse for the fishes.” — Oliver Wendell Holmes, M. D., Professor of Medicine , Harvard “With all his conscience and one eye askew, So false he […]

June 24, 2014 / DrKSSMDPhD

Hepatitis with a C

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

roblites on written by reader

The eyes and ears team for bio trials / Mar 15, 3:18pm

".......Israel's Galmed ($GLMD) banked $38 million in a 2.8 million-share offering, pricing at $13.50 after upping its t...

berthuis on written by reader

NASH: An All-Too-Common Liver Disease and a Company Aiming to Treat It / Mar 14, 2:00pm

Aramchol might be a good alternative for OCA, no problems with cholesterol. In animals it dissolves cholesterol gallston...

DrKSSMDPhD on written by reader

NASH: An All-Too-Common Liver Disease and a Company Aiming to Treat It / Mar 13, 1:57pm

Galmed (GLMD) looks rather interesting. IPO today. I am not in yet, still reviewing their studies, but it is one more re...